MedTrace Logo

A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC

NCT02852083 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2018-01-18

No results posted yet for this study

Summary

This is a Phase II, multicentre, open-label, randomized, and controlled study, evaluating the efficacy and safety of combined modularized treatment of treosulfan, pioglitazone and clarithromycin in patients with with squamous and non- squamous cell lung cancer, respectively after platin failure.

Conditions

Interventions

DRUG

Pioglitazone

Pioglitazone 25 mg once daily, p.o.

DRUG

nivolumab

3 mg per kilogram of body weight every 2 weeks, p.o. (standard treatment)

DRUG

Treosulfan

Treosulfan 250 mg twice daily, p.o.

DRUG

Clarithromycin

Clarithromycin 250 mg twice daily p.o.

Sponsors & Collaborators

  • The Anticancer Fund

    collaborator UNKNOWN

  • University Hospital Regensburg

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2019-07-31
Completion
2020-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02852083 on ClinicalTrials.gov